December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Orbis Medicines

News headline image
Orbis Medicines Enters Multi-Target Drug Discovery Partnership with Novo Nordisk Worth up to USD 1.4 Billion
From Orbis Medicines
Via Business Wire
News headline image
Orbis Medicines Accelerates Next-Generation Oral Macrocycle Platform with Enhanced Artificial Intelligence Capabilities of Gefion Supercomputer
From Orbis Medicines
Via Business Wire
News headline image
Orbis Medicines Names Veteran R&D Leader Mikael Dolsten Board Chair
From Orbis Medicines
Via Business Wire
News headline image
Orbis Medicines Raises EUR 90 Million Series A Funding Round to Develop Pipeline of Oral Macrocycles
From Orbis Medicines
Via Business Wire
News headline image
Orbis Medicines and Vivtex Form Research & Exclusive Licensing Collaboration to Support Orbis Development of Next-Generation Orally Dosable ‘nCycles’
From Orbis Medicines
Via Business Wire
News headline image
Orbis Medicines Launches with €26 Million Seed Financing to Transform Macrocycle Drug Development through Next-Generation Orally Dosable ‘nCycles’
From Orbis Medicines
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.